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Fluoroquinolone resistance in pneumococci is known to be associated with the efflux
pump, PmrA. However, there may be other efflux systems that also cause drug
resistance. Two types of mutants were studied. The efflux phenotype from mutants
selected by sub-MIC levofloxacin or gemifloxacin was transformed into R6. These
transformants did not show increased pmrA transcripts in Northern blots; insertional
inactivation of pmrA in the transformants did not abolish the efflux phenotype. A second
set of efflux phenotype mutants was selected in R6:cat by ethidium bromide but not by
norfloxacin; accumulation of ethidium bromide in the one among these mutants studied
was reduced in comparison to its parent. This evidence suggests that systems other than
PmrA can contribute to efflux-mediated resistance in pneumococci.
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Multidrug efflux resistance is well described in
Streptococcus pneumoniae [1–3]. It is associated with
a reduction in the susceptibility to some fluoro-
quinolones, such as norfloxacin and ciprofloxacin,
as well as to several unrelated dyes (e.g. acriflavine
and ethidium bromide) and disinfectants (e.g.
cetrimide). In common with pumps of the major
facilitator and ABC superfamilies, that described
in pneumococci is inhibited by reserpine.
Increased expression of a 399 amino acid protein
(PmrA) of the major facilitator superfamily of
efflux pumps has been implicated in multidrug
efflux resistance in pneumococci [4].
In other Gram-positive bacteria, multiple efflux
systems have been shown to occur in the same
organism. For example, in Bacillus subtilis the over-
expression of the efflux pumps Bmr or Blt causes a
reduction in the susceptibility to several com-
pounds, including norfloxacin and ethidium bro-
mide [5]. Similarly, in Staphylococcus aureus, at least
two multidrug efflux pumps have been shown to
exist [6].
As several multidrug efflux systems can occur in
the same organism and often have overlapping
substrates, we undertook this study to determine
whether efflux pumps other than PmrA are likely
to contribute to multidrug resistance in pneumo-
cocci. Since bacteria may have more than one such
efflux pump, we have studied mutants derived by
two different means to see if these mutants would
have different efflux pumps overexpressed.
The first mutants we studied, LEV1 and GEM11,
had been selected from clinical isolates by serial
subculture in the presence of low levels of levo-
floxacin and gemifloxacin, respectively [7,8]. Both
mutants had previously been shown to have a
phenotype consistent with efflux-mediated fluor-
oquinolone resistance [7,8], in addition to topoi-
somerase II mutations. To study the efflux
resistance in these strains apart from the effects
of their topoisomerase mutations, the susceptible
laboratory strain R6 was transformed by a stan-
dard method [4] using chromosomal DNA
extracted from LEV1 and GEM11 as donor
DNA. Transformants were selected with ethidium
bromide (4 mg/L), which is a pump substrate and
has been used to select efflux pump mutants
in pneumococci [1]. To control for spontaneous
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ethidium bromide-resistant mutants, an aliquot of
R6 cells (which was not exposed to transforming
DNA) was taken through the transformation proce-
dure in parallel; no spontaneous ethidium bromide-
resistant mutants were detected in this control.
The transformation of strain R6 with chromo-
somal DNA from efflux mutants LEV1 and GEM11
yielded transformants selected with ethidium bro-
mide (transformation frequencies 2 105 and
7 105, respectively; parC mutant donor control
5 105 selected on norfloxacin 4 mg/L). A stan-
dard agar dilution method [9] was employed to
determine the susceptibility of transformants to
several fluoroquinolones and known efflux pump
substrates; the effect of the efflux pump inhibitor,
reserpine (10 mg/L), on the norfloxacin minimum
inhibitory concentration (MIC) was also tested as
previously [2]. Phenotypically typical transfor-
mants, R6LEV1 and R6GEM11, were chosen for
further study. Table 1 shows the susceptibility of
these two transformants. Both showed a two- to
four-fold rise in the MIC of norfloxacin compared
with R6, which was reduced four- to eight-fold in
the presence of reserpine. The MICs of ethidium
bromide and acriflavine were increased four-to-
16-fold. The MICs of moxifloxacin and gemiflox-
acin were not significantly increased. The MICs of
R6LEV1 and R6GEM11 are consistent with an
efflux phenotype [2], since they show low-level
resistance to unrelated drugs. Insertional inactiva-
tion of pmrA with cat [4] in R6LEV1 and R6GEM11
did not alter this phenotype. This indicates that the
efflux phenotype in R6LEV1 and R6GEM11 is
independent of PmrA.
To see whether or not the efflux phenotype
transformants R6LEV1 and R6GEM11 had
increased expression of pmrA, Northern blotting
was performed on total RNA on pneumococci
grown to mid-log phase. A derivative of R6 with
increased expression of pmrA (R6N [4]) was used
as a positive control for this blotting. Northern blot
analysis of R6LEV1 and R6GEM11 for pmrA did
not show increased transcription compared with
the parent strain R6. These results indicate that in
these strains, the efflux phenotype was indepen-
dent of increased transcription of pmrA.
The second set of mutants we studied were
those arising from ethidium bromide selection of
a strain (R6:cat) in which pmrA was insertionally
inactivated. A similar approach has been used by
Kaatz et al. [6] in Staphylococcus aureus to demon-
strate the presence of a multidrug efflux system T
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other than NorA. Insertional inactivation was
done in the standard laboratory strain R6, with
a chloramphenicol resistance cassette (cat), by the
method previously described [4]. To select for
mutants of R6:cat, approximately 109 CFU of S.
pneumoniae strain R6:cat were inoculated on
Columbia blood agar containing either norfloxacin
or ethidium bromide at 1, 2, 4 or 8 their
respective MICs of 2 mg/L and 1 mg/L. After
incubation for 3 days at 35–37 8C in 4–6% CO2,
representative mutants were subcultured on
Columbia blood agar containing 8 mg/L chloram-
phenicol.
Of 68 norfloxacin-selected mutants examined,
none showed a greater than two-fold reduction in
their susceptibility to norfloxacin in the presence
of reserpine. Since the reduction in their suscept-
ibility, as determined by agar dilution testing, was
not significant (i.e. 2-fold increase in MIC), they
were not further studied. However, two mutants
(R6:cat-1 and R6:cat-2) selected with ethidium bro-
mide at a concentration of 8MIC were found to
be presumptive efflux mutants. Both showed an
eight-fold rise in MIC of norfloxacin compared
with the parent strain (R6:cat), which was reduced
four-fold in the presence of reserpine. The mutants
also showed significantly raised MICs to ethidium
bromide and acriflavine (Table 1) compared with
the parent.
It is of interest that efflux mutants could only be
selected from R6:cat with ethidium bromide; none
were selected with norfloxacin. In other studies
using different strains, both ethidium bromide and
norfloxacin have been shown to readily select
efflux mutants from S. pneumoniae [1,2]. It is pos-
sible that the inability of norfloxacin to select efflux
mutants from R6:cat merely reflects differences
between strains, or that ethidium bromide is a
more suitable selection agent for efflux mutants.
The mutants that we selected with norfloxacin
probably represent topoisomerase mutants: their
susceptibility to norfloxacin was not significantly
affected by reserpine, nor was their susceptibility
to ethidium bromide reduced.
To further confirm the efflux phenotype in the
ethidium bromide-selected mutants, ethidium
bromide accumulation was determined in R6:cat
and R6:cat-2, as previously [2]. Mutant R6:cat-2
accumulated less ethidium bromide than the par-
ent strain R6:cat (Figure 1). After 10 min, the accu-
mulation was 26% lower in the mutant than in the
parent (Student’s t-test, P< 0.05).
Finally, Southern blot analysis of chromosomal
DNA (digestion with PstI or HindIII and probed
for pmrA and cat) from R6:cat and its ethidium
bromide-selected efflux mutants was performed as
previously described [4]. This blotting confirmed
(data not shown) the presence of a single copy of
pmrA on the chromosome of R6:cat, R6:cat-1 and
R6:cat-2. It also showed that cat was within pmrA
for the three strains. These findings indicate that in
the ethidium bromide-selected mutants, the efflux
phenotype was unlikely to be due to expression of
pmrA or the effects of cat insertion elsewhere in the
chromosome.
We have found multidrug efflux-mediated
resistance in mutants R6LEV1 and R6GEM1 that
is not associated with increased expression of
pmrA. We have also selected multidrug efflux
mutants (R6:cat-1 and R6:cat-2) in the presence
of an inactivated copy of pmrA. This is good
evidence that systems other than PmrA can con-
tribute to efflux-mediated resistance in pneumo-
cocci.
The phenotypes that we have described do not
cause significant resistance to fluoroquinolones,
such as gemifloxacin and moxifloxacin, with anti-
pneumococcal activity. However, it is of interest
that levofloxacin and gemifloxacin may select for
such phenotypes. In addition, the pump(s) sys-
tem(s) indicated by our experiments may be of
relevance to other antibiotics now and in the
future, and will help to define efflux pump sys-
tems in pneumococci. Genome sequencing of
strains TIGR4 [10] and R6 [11] indicates a large
number of putative multifacilitator and ABC
Figure 1 Accumulation of ethidium bromide by Strepto-
coccus pneumoniae strain R6:cat (parent; squares) and R6:cat-
2 (mutant; triangles). Each point is the mean of three
individual experiments; error bars represent  standard
deviation. Fluorescent emission at 600 nm is proportional
to accumulation of ethidium bromide.
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superfamily efflux pump genes. In this latter
group of pumps, there are approximately 70 with-
out assigned function. The role that these putative
pump genes play in non-PmrA-mediated drug
resistance needs further study. It is likely that
the efflux pumps found in pneumococci, as in
other bacteria, will have overlapping substrate
specificity and complex regulation of their expres-
sion [5,6].
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